Key Highlights
- India’s Sun Pharmaceutical Industries will acquire Organon & Co through an all-cash transaction valuing the firm at $11.75 billion, debt included.
- Shareholders of Organon will be paid $14.00 in cash for each share they own.
- Shares of Organon jumped approximately 31% on Friday following initial reports, then added another ~15% during premarket hours on Monday.
- Once merged, the entity will be positioned among the world’s top 25 pharmaceutical firms, generating pro forma revenues of $12.4 billion.
- The transaction is anticipated to finalize in early 2027, subject to regulatory clearances and shareholder consent.
Sun Pharma, which holds the position as India’s premier pharmaceutical manufacturer, revealed on Sunday its intention to purchase New Jersey-headquartered Organon & Co in a cash-only transaction totaling $11.75 billion with debt. The acquisition price stands at $14.00 for every share.
Shares of Organon had already soared close to 31% on Friday following an Economic Times report indicating that Sun Pharma was negotiating to purchase the firm for approximately $13 billion. After Sunday’s formal announcement of the agreement, Organon climbed an additional ~15% during early Monday premarket activity.
The cumulative gain across both sessions represents an approximate 46% surge from the stock’s pre-announcement trading levels.
Organon emerged as an independent entity following its 2021 separation from Merck, concentrating on women’s healthcare, biosimilar medications, and established branded pharmaceutical products. The company generated $6.2 billion in revenue and achieved adjusted EBITDA of $1.9 billion during 2025.
Sun Pharma indicated it will finance the acquisition using a combination of available cash reserves and committed bank credit facilities. The boards of both organizations have granted their approval to the transaction.
Strategic Benefits for Sun Pharma
The acquisition provides Sun Pharma with a portfolio exceeding 70 pharmaceutical products distributed across more than 140 nations worldwide. It also establishes the Indian pharmaceutical giant’s presence in the biosimilars sector, where the merged organization would rank as the seventh-largest competitor on a global scale.
Organon maintains significant market presence in the United States, Europe, China, Canada, and Brazil. The company manages six production facilities located throughout the European Union and emerging market regions.
Dr. Kunal, an analyst at Macquarie, characterized the transaction as “strategically and financially compelling” for Sun. He highlighted that the merged company will derive 27% of its revenue from innovative pharmaceutical products, compared to Sun Pharma’s current 20%.
Sun Pharma presently focuses on dermatology, ophthalmology, and onco-dermatology within its innovative medicines division. Incorporating Organon’s women’s health product line would significantly broaden that therapeutic scope.
The combined organization would also achieve a top-three ranking in the global women’s health pharmaceutical market.
Debt Considerations in the Deal
Organon entered this transaction with $8.6 billion in outstanding debt obligations and maintained a cash position of $574 million as of December 2025. The company’s net debt to EBITDA multiple was at 4 times entering the agreement.
Sun Pharma, conversely, maintained a net positive financial position prior to announcing the acquisition. Following deal completion, the combined company is forecast to operate with a net debt to EBITDA ratio of 2.3 times.
Bhavesh Shah from Equirus Capital observed that transactions of this magnitude can prove “value accretive over the medium to long term,” though he cautioned about near-term uncertainties including integration expenses and operational implementation hurdles.
This marks the sixth major acquisition Sun Pharma has completed over the past 16 years. Previous transactions include a 2007 purchase of financially troubled Israeli company Taro Pharma and a 2014 acquisition of Ranbaxy Laboratories valued at approximately $3.2 billion.
The Organon acquisition is projected to elevate Sun Pharma into the ranks of the top 25 global pharmaceutical corporations, with the merged entity generating combined pro forma revenues of $12.4 billion.
The deal is scheduled to reach completion in early 2027, contingent upon receiving necessary regulatory approvals and shareholder authorization.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
